Journals / The Anatolian Journal of Cardiology / 2022 / Cilt: 26 - Sayı: 2

Nanoparticle, a promising therapeutic strategy for the treatment of infective endocarditis

Pages
90–99
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, we review the latest advances in nanoparticles against drug-resistant bacteria in biofilm and recommends nanoparticles as an alternative strategy to the antibiotic treatment of IE.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infective endocarditis (IE) has been recognized as a biofilm-related disease caused by pathogenic microorganisms, such as bacteria and fungi that invade and damage the heart valves and endocardium.
📊
Key Findings & Data:There are many difficulties and challenges in the antimicrobial treatment of IE, including multi-drug resistant pathogens, large dose of drug administration with following side effects, and poor prognosis.
💡
Conclusion & Impact:In this article, we review the latest advances in nanoparticles against drug-resistant bacteria in biofilm and recommends nanoparticles as an alternative strategy to the antibiotic treatment of IE.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Infective endocarditis (IE) has been recognized as a biofilm-related disease caused by pathogenic microorganisms, such as bacteria and fungi that invade and damage the heart valves and endocardium. There are many difficulties and challenges in the antimicrobial treatment of IE, including multi-drug resistant pathogens, large dose of drug administration with following side effects, and poor prognosis. For the past few years, the development of nanotechnology has promoted the use of nanoparticles as antimicrobial nano-pharmaceuticals or novel drug delivery systems (NDDS) in antimicrobial therapy for chronic infections and biofilm-related infectious disease as these molecules exhibit several advantages. Therefore, nanoparticles have a potential role to play in solving problems in the treatment of IE, including improving antimicrobial activity, increasing drug bioavailability, minimizing frequency of drug administration, and preventing side effects. In this article, we review the latest advances in nanoparticles against drug-resistant bacteria in biofilm and recommends nanoparticles as an alternative strategy to the antibiotic treatment of IE.

🔖

Cite This Article

TONG, Q., Lİ, T., WANG, Z., QIAN, Y., JIANG, L. (2022). Nanoparticle, a promising therapeutic strategy for the treatment of infective endocarditis. The Anatolian Journal of Cardiology, Cilt: 26 - Sayı: 2, 90–99. https://ajindex.com/articles/407462

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Emerich DF, Thanos CG. Nanotechnology and medicine. Expert Opin Biol Ther 2003
  2. [Crossref] 2. Feynman RP. There’s plenty of room at the bottom. Journal of Microelectromechanical Systems 1992
  3. [Crossref] 3. Chaturvedi VK, Singh A, Singh VK, Singh MP. Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy. Curr Drug Metab 2019
  4. [Crossref] 4. Liu Y, Shi L, Su L, van der Mei HC, Jutte PC, Ren Y, et al. Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control. Chem Soc Rev 2019
  5. [Crossref] 5. Palazzolo JS, Westein E, Hagemeyer CE, Wang TY. Targeting Nanotechnologies for the Treatment of Thrombosis and Cardiovascular Disease. Semin Thromb Hemost 2020
  6. [Crossref] 6. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008
  7. [Crossref] 7. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 2016
  8. [Crossref] 8. Jensen AD, Bundgaard H, Butt JH, Bruun NE, Voldstedlund M, Torp-Pedersen C, et al. Temporal changes in the incidence of infective endocarditis in Denmark 1997-2017: A nationwide study. Int J Cardiol 2021
  9. [Crossref] 9. Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Pettersson GB, et al. Challenges in Infective Endocarditis. J Am Coll Cardiol 2017
  10. [Crossref] 10. Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, Lagacé J. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994
  11. [Crossref] 11. Werdan K, Dietz S, Löffler B, Niemann S, Bushnaq H, Silber RE, et al. Mechanisms of infective endocarditis: pathogen-host interaction and risk states. Nat Rev Cardiol 2014
  12. [Crossref] 12. Vestby LK, Grønseth T, Simm R, Nesse LL. Bacterial Biofilm and its Role in the Pathogenesis of Disease. Antibiotics (Basel) 2020
  13. [Crossref] 13. Del Pozo JL. Biofilm-related disease. Expert Rev Anti Infect Ther 2018
  14. [Crossref] 14. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003
  15. [Crossref] 15. Marrie TJ, Cooper JH, Costerton JW. Ultrastructure of cardiac bacterial vegetations on native valves with emphasis on alterations in bacterial morphology following antibiotic treatme